2Pereyre S,Guyot C,Renaudin H,et al.In vitro selection and character -rization of resistance to macrolides and related antibiotics in Mycoplasma pnuemoniae. Antimicrob Agents Chemother,2004 ,48:460-465.
3Mansel JK, Rosenom EC, Martin JW, et al. Mycoplasma pneumoniae pneumonia. Chest, 1989,95 : 639-646.
4Juliy JG. Current status of the mollicute flora of humans. Clin Infect Dis, 1993,17 ; S2-S9.
5Krause DC, Balish MF. Structure, function, and assembly of the terminal organelle of mycoplasma pneumoniae. FEMS Microbiol Lett,2001.198: 1- 7.
6Ferwerda A,Moll HA, de Groot R. Respiratory tract infections by mycoplasma pneumoniae in children:a review of diagnostic and therapeutic measures. Eur J Pediatr.2000,160:483-491.
7Redisic M,Torn A, Gutierrez P, et al. Severe acute lung injury caused by mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis,2000,31 : 1507-1511.
8Hanaka H, Koba H, Honma S, et al. ReLationships between radiologieal pattern and cell-mediated immune response in myeoplasma pneumoniae pneumonia. Eur Respir J, 1996,9 : 669- 672.
9Tanaka H. Yamagishi M, Ade S, et al. The effect of interleukin- 2 and cyclosporin A on the ceil-mediated immunity in mycoplasma pneumonia of mice. Am J Respir Crit Care Med, 1994,149:A872.
10Yang J, Hooper WC, Phillips DJ, et al. Regulation of proinflammatory cytokines in human hung epithelial cells infected with mycoplasma pneumoniae. Infect Immun, 2002,70 : 3649-3655.
